Updated treatment options for immune thrombocytopenia

Philip Choi^{1

2}, Eileen Merriman³, Ashwini Bennett^{4

5}, Anoop Enjeti^{6

7

8}, Chee Wee Tan⁹, Isaac Goncalves^{10

11}, Danny Hsu^{12

13}, Robert Bird¹⁴

Affiliations

¹ The Canberra Hospital, Canberra, Australian Capital Territory, Australia.
² John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia.
³ North Shore Hospital, Auckland, New Zealand.
⁴ Monash Health, Melbourne, Victoria, Australia.
⁵ Monash University, Melbourne, Victoria, Australia.
⁶ Calvary Mater, Newcastle, New South Wales, Australia.
⁷ University of Newcastle, Newcastle, New South Wales, Australia.
⁸ NSW Health Pathology, Newcastle, New South Wales, Australia.
⁹ Royal Adelaide Hospital, Adelaide, South Australia, Australia.
¹⁰ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
¹¹ Royal Melbourne Hospital, Melbourne, Victoria, Australia.
¹² Liverpool Hospital, Sydney, New South Wales, Australia.
¹³ University of New South Wales, Kensington, New South Wales, Australia.
¹⁴ Princess Alexandria Hospital, Brisbane, Queensland, Australia.

Editorial

Philip Choi et al. Intern Med J. 2024 Feb.

. 2024 Feb;54(2):201-203.

doi: 10.1111/imj.16246. Epub 2023 Nov 17.

Philip Choi^{1

2}, Eileen Merriman³, Ashwini Bennett^{4

5}, Anoop Enjeti^{6

7

8}, Chee Wee Tan⁹, Isaac Goncalves^{10

11}, Danny Hsu^{12

13}, Robert Bird¹⁴

¹ The Canberra Hospital, Canberra, Australian Capital Territory, Australia.
² John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia.
³ North Shore Hospital, Auckland, New Zealand.
⁴ Monash Health, Melbourne, Victoria, Australia.
⁵ Monash University, Melbourne, Victoria, Australia.
⁶ Calvary Mater, Newcastle, New South Wales, Australia.
⁷ University of Newcastle, Newcastle, New South Wales, Australia.
⁸ NSW Health Pathology, Newcastle, New South Wales, Australia.
⁹ Royal Adelaide Hospital, Adelaide, South Australia, Australia.
¹⁰ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
¹¹ Royal Melbourne Hospital, Melbourne, Victoria, Australia.
¹² Liverpool Hospital, Sydney, New South Wales, Australia.
¹³ University of New South Wales, Kensington, New South Wales, Australia.
¹⁴ Princess Alexandria Hospital, Brisbane, Queensland, Australia.

No abstract available

References

1. Choi PY, Merriman E, Bennett A, Enjeti AK, Tan CW, Goncalves I et al. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Med J Aust 2022; 216: 43-52.
1. Olney HJ, Fogarty PF, Tarantino MD, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in splenectomized versus nonsplenectomized patients with chronic ITP in the RAISE study. Blood 2010; 116: 2512.
1. Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica 2017; 102: 1342-1351.
1. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3: 3829-3866.
1. Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol 2022; 197: 359-366.